Montanova Capital LLC Raises Stake in InflaRx N.V. $IFRX

Montanova Capital LLC raised its holdings in InflaRx N.V. (NASDAQ:IFRX) by 189.1% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 22,933,910 shares of the company’s stock after purchasing an additional 15,000,000 shares during the quarter. InflaRx comprises approximately 0.9% of Montanova Capital LLC’s portfolio, making the stock its 29th largest holding. Montanova Capital LLC owned about 0.16% of InflaRx worth $51,372,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in IFRX. Sanctuary Advisors LLC purchased a new position in shares of InflaRx during the second quarter worth about $25,000. Cubist Systematic Strategies LLC raised its stake in InflaRx by 33.9% during the 1st quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company’s stock valued at $31,000 after acquiring an additional 7,616 shares during the last quarter. HRT Financial LP acquired a new stake in InflaRx during the 4th quarter worth approximately $47,000. Concurrent Investment Advisors LLC lifted its position in InflaRx by 56.9% during the 4th quarter. Concurrent Investment Advisors LLC now owns 52,951 shares of the company’s stock worth $53,000 after acquiring an additional 19,200 shares during the period. Finally, Insigneo Advisory Services LLC purchased a new position in shares of InflaRx in the 4th quarter valued at approximately $61,000. Institutional investors and hedge funds own 42.39% of the company’s stock.

Analysts Set New Price Targets

IFRX has been the subject of several analyst reports. HC Wainwright upped their price target on InflaRx from $6.00 to $8.00 and gave the stock a “buy” rating in a research note on Monday, May 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of InflaRx in a research report on Wednesday, June 24th. Wall Street Zen raised shares of InflaRx from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Raymond James Financial upgraded shares of InflaRx from an “outperform” rating to a “strong-buy” rating and upped their price objective for the stock from $7.00 to $9.00 in a research report on Wednesday, May 13th. Finally, Zacks Research cut shares of InflaRx from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 25th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $7.33.

InflaRx Price Performance

InflaRx stock opened at $2.13 on Tuesday. The stock’s 50 day moving average price is $1.99 and its 200 day moving average price is $1.67. InflaRx N.V. has a 1-year low of $0.80 and a 1-year high of $2.95. The company has a market cap of $313.90 million, a PE ratio of -3.67 and a beta of 2.48.

InflaRx (NASDAQ:IFRX) last released its quarterly earnings data on Friday, August 7th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.04). On average, equities research analysts anticipate that InflaRx N.V. will post -0.31 EPS for the current fiscal year.

About InflaRx

InflaRx N.V. is a clinical?stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement?1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX?1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro?inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high?unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.